

David P Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3101288/publications.pdf>

Version: 2024-02-01

91
papers

2,387
citations

201674

27
h-index

233421

45
g-index

91
all docs

91
docs citations

91
times ranked

3718
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia. <i>Cancer Epidemiology</i> , 2022, 78, 102159.	1.9	1
2	Socioeconomic differences in prostate cancer treatment: A systematic review and meta-analysis. <i>Cancer Epidemiology</i> , 2022, 79, 102164.	1.9	2
3	Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study. <i>British Journal of Cancer</i> , 2022, 127, 735-746.	6.4	1
4	Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review. <i>Quality of Life Research</i> , 2021, 30, 345-366.	3.1	8
5	Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e204-e216.	2.9	27
6	Patterns of care for men with prostate cancer: the 45 and Up Study. <i>Medical Journal of Australia</i> , 2021, 214, 271-278.	1.7	17
7	Avoiding the "survivorship abyss": Qualitative insights from 15-year prostate cancer survivors. <i>Psycho-Oncology</i> , 2021, 30, 1745-1755.	2.3	4
8	Patterns of care for prostate cancer treatment and improving outcomes "are national registries the answer?". <i>BJU International</i> , 2021, 128 Suppl 1, 6-8.	2.5	11
9	Characteristics Associated with the Use of Diagnostic Prostate Biopsy and Biopsy Outcomes in Australian Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1735-1743.	2.5	2
10	Measuring psychosocial outcomes of men living with prostate cancer: feasibility of regular assessment of patient-reported outcomes. <i>European Journal of Cancer Care</i> , 2021, 30, e13393.	1.5	4
11	Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. <i>BMJ, The</i> , 2020, 371, m3503.	6.0	43
12	Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. <i>Scientific Reports</i> , 2020, 10, 7736.	3.3	11
13	Long-term unmet supportive care needs of prostate cancer survivors: 15-year follow-up from the NSW Prostate Cancer Care and Outcomes Study. <i>Supportive Care in Cancer</i> , 2020, 28, 5511-5520.	2.2	23
14	Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 134-143.	1.8	4
15	Patterns of prostate-specific antigen testing by remoteness of residence and socio-economic status: An Australian population-based study. <i>Australian Journal of Rural Health</i> , 2019, 27, 216-223.	1.5	9
16	Factors associated with the use of diet and the use of exercise for prostate cancer by long-term survivors. <i>PLoS ONE</i> , 2019, 14, e0223407.	2.5	4
17	The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values. <i>Medical Journal of Australia</i> , 2019, 210, 499-506.	1.7	38
18	Title is missing!. , 2019, 14, e0223407.		0

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2019, 14, e0223407.		0
20	Title is missing!. , 2019, 14, e0223407.		0
21	Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review. Supportive Care in Cancer, 2018, 26, 1061-1076.	2.2	5
22	Factors associated with prostate specific antigen testing in Australians: Analysis of the New South Wales 45 and Up Study. Scientific Reports, 2018, 8, 4261.	3.3	12
23	Development of Indicators to Assess Quality of Care for Prostate Cancer. European Urology Focus, 2018, 4, 57-63.	3.1	17
24	Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer. European Urology, 2018, 73, 859-867.	1.9	33
25	“Prostate cancer is far more hidden” – Perceptions of stigma, social isolation and help-seeking among men with prostate cancer. European Journal of Cancer Care, 2018, 27, e12790.	1.5	69
26	Low risk prostate cancer and an opportunity lost: more activity required in active surveillance. Medical Journal of Australia, 2018, 208, 430-431.	1.7	0
27	A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial. Implementation Science, 2018, 13, 43.	6.9	26
28	An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: Results from the New South Wales Cancer Registry. Scientific Reports, 2018, 8, 7167.	3.3	12
29	Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data. PLoS ONE, 2018, 13, e0198679.	2.5	24
30	Associations between sun sensitive pigimentary genes and serum prostate specific antigen levels. PLoS ONE, 2018, 13, e0193893.	2.5	4
31	Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors. PLoS ONE, 2018, 13, e0193686.	2.5	15
32	Predictors of surgical approach for the management of renal cell carcinoma: a population-based study from New South Wales. ANZ Journal of Surgery, 2017, 87, E193-E198.	0.7	12
33	A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer. Supportive Care in Cancer, 2017, 25, 3095-3102.	2.2	12
34	What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 152-159.	1.1	5
35	Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 291-297.	1.6	69
36	Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival. Cancer Medicine, 2017, 6, 2188-2193.	2.8	25

#	ARTICLE	IF	CITATIONS
37	New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications. <i>Psycho-Oncology</i> , 2017, 26, 873-913.	2.3	55
38	Cancer-related hospitalisations and unknown stage prostate cancer: a population-based record linkage study. <i>BMJ Open</i> , 2017, 7, e014259.	1.9	9
39	Adult body size, sexual history and adolescent sexual development, may predict risk of developing prostate cancer: Results from the New South Wales Lifestyle and Evaluation of Risk Study (CLEAR). <i>International Journal of Cancer</i> , 2017, 140, 565-574.	5.1	30
40	Financial toxicity: a potential side effect of prostate cancer treatment among Australian men. <i>European Journal of Cancer Care</i> , 2017, 26, e12392.	1.5	73
41	Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 160-171.	1.1	10
42	Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study. <i>PLoS ONE</i> , 2017, 12, e0171013.	2.5	7
43	Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data. <i>PLoS ONE</i> , 2017, 12, e0180033.	2.5	26
44	Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e216.	1.0	2
45	The role of mindfulness in distress and quality of life for men with advanced prostate cancer. <i>Quality of Life Research</i> , 2016, 25, 3027-3035.	3.1	24
46	Volume-outcome relationship in penile cancer treatment: a population based patterns of care and outcomes study from Australia. <i>BJU International</i> , 2016, 118, 35-42.	2.5	8
47	Poor survival of females with bladder cancer is limited to those aged 70 years or over: a population-wide linkage study, New South Wales, Australia. <i>Cancer Medicine</i> , 2015, 4, 1145-1152.	2.8	12
48	Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study. <i>BJU International</i> , 2015, 116, 18-25.	2.5	29
49	Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia. <i>BJU International</i> , 2015, 115, 16-23.	2.5	18
50	Prostate cancer prevalence in New South Wales Australia: A population-based study. <i>Cancer Epidemiology</i> , 2015, 39, 29-36.	1.9	11
51	An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?. <i>World Journal of Urology</i> , 2015, 33, 1677-1687.	2.2	27
52	A population-based study of progression to metastatic prostate cancer in Australia. <i>Cancer Epidemiology</i> , 2015, 39, 617-622.	1.9	20
53	Geographic Disparities in Prostate Cancer Outcomes - Review of International Patterns. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 1259-1275.	1.2	39
54	Geographic variation in prostate cancer survival in New South Wales. <i>Medical Journal of Australia</i> , 2014, 200, 586-590.	1.7	48

#	ARTICLE	IF	CITATIONS
55	The ban on phenacetin is associated with changes in the incidence trends of upper urinary tract cancers in Australia. Australian and New Zealand Journal of Public Health, 2014, 38, 455-458.	1.8	6
56	A comprehensive evaluation of bladder cancer epidemiology and outcomes in Australia. International Urology and Nephrology, 2014, 46, 1351-1360.	1.4	16
57	The relationship between solar UV exposure, serum vitamin D levels and serum prostate-specific antigen levels, in men from New South Wales, Australia: the CHAMP study. World Journal of Urology, 2014, 32, 1251-1257.	2.2	3
58	Clinician-led improvement in cancer care (CLICC) - testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial - study protocol. Implementation Science, 2014, 9, 64.	6.9	17
59	Relationship between Lifestyle and Health Factors and Severe Lower Urinary Tract Symptoms (LUTS) in 106,435 Middle-Aged and Older Australian Men: Population-Based Study. PLoS ONE, 2014, 9, e109278.	2.5	38
60	A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer. BMC Cancer, 2013, 13, 89.	2.6	16
61	Sociodemographic and health-related predictors of self-reported mammogram, faecal occult blood test and prostate specific antigen test use in a large Australian study. BMC Public Health, 2013, 13, 429.	2.9	36
62	Lower urinary tract symptoms in relation to region of birth in 95,393 men living in Australia: the 45 and Up Study. World Journal of Urology, 2013, 31, 673-682.	2.2	15
63	Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry. Cancer Epidemiology, 2013, 37, 813-819.	1.9	18
64	Cancer incidence and mortality in people aged less than 75 years: Changes in Australia over the period 1987-2007. Cancer Epidemiology, 2013, 37, 780-787.	1.9	20
65	The association of ultraviolet radiation-B (305Ånm), season of diagnosis, and latitude on the survival outcome of prostate cancer in the high UV environment of Australia. Cancer Causes and Control, 2013, 24, 2005-2011.	1.8	4
66	Risk factors for erectile dysfunction in a cohort of 108 477 Australian men. Medical Journal of Australia, 2013, 199, 107-111.	1.7	68
67	Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. British Journal of Cancer, 2012, 106, 638-645.	6.4	36
68	Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study. Medical Journal of Australia, 2012, 196, 395-398.	1.7	20
69	Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: A case-control study. International Journal of Cancer, 2012, 131, E726-32.	5.1	28
70	Authors' reply to: Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: A case-control study. International Journal of Cancer, 2012, 131, 2206-2207.	5.1	0
71	A compact mechatronic system for 3D ultrasound guided prostate interventions. Medical Physics, 2011, 38, 1055-1069.	3.0	28
72	Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study. BMC Health Services Research, 2011, 11, 253.	2.2	32

#	ARTICLE	IF	CITATIONS
73	Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study. <i>BMJ Open</i> , 2011, 1, e000104-e000104.	1.9	10
74	Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality. <i>Medical Journal of Australia</i> , 2010, 192, 110-110.	1.7	0
75	Impact of Australian celebrity diagnoses on prostate cancer screening. <i>Medical Journal of Australia</i> , 2009, 191, 574-575.	1.7	5
76	Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality. <i>Medical Journal of Australia</i> , 2009, 191, 199-200.	1.7	3
77	Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up Study. <i>BMC Public Health</i> , 2009, 9, 144.	2.9	49
78	Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. <i>BMJ: British Medical Journal</i> , 2009, 339, b4817-b4817.	2.3	227
79	Patterns of surgical care for prostate cancer in NSW, 1993-2002: rural/urban and socio-economic variation. <i>Australian and New Zealand Journal of Public Health</i> , 2008, 32, 417-420.	1.8	32
80	3D transrectal ultrasound prostate biopsy using a mechanical imaging and needle-guidance system. <i>Proceedings of SPIE</i> , 2008, , .	0.8	0
81	Mechanically assisted 3D ultrasound guided prostate biopsy system. <i>Medical Physics</i> , 2008, 35, 5397-5410.	3.0	116
82	Prostate cancer and prostate-specific antigen testing in New South Wales. <i>Medical Journal of Australia</i> , 2008, 189, 315-318.	1.7	31
83	A compact robotic apparatus and method for 3-D ultrasound guided prostate therapy. , 2007, , .		1
84	Age, Health, and Education Determine Supportive Care Needs of Men Younger Than 70 Years With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2560-2566.	1.6	126
85	Clinicians' attitudes to prostate cancer peer-support groups. <i>BJU International</i> , 2007, 99, 68-71.	2.5	36
86	Remoteness of residence and survival from cancer in New South Wales. <i>Medical Journal of Australia</i> , 2004, 180, 618-622.	1.7	161
87	Estimating Regional Variation in Cancer Survival: A Tool for Improving Cancer Care. <i>Cancer Causes and Control</i> , 2004, 15, 611-618.	1.8	26
88	Observations on the effect of abolishing analgesic abuse and reducing smoking on cancers of the kidney and bladder in New South Wales, Australia, 1972-1995. <i>Cancer Causes and Control</i> , 1999, 10, 303-311.	1.8	14
89	Breast cancer in New South Wales in 1972-1995: Tumor size and the impact of mammographic screening. , 1999, 81, 877-880.		44
90	Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. <i>Medical Journal of Australia</i> , 1998, 169, 17-20.	1.7	66

#	ARTICLE	IF	CITATIONS
91	Socioeconomic differentials in cancer incidence and mortality in urban New South Wales, 1987â€“1991. Australian and New Zealand Journal of Public Health, 1996, 20, 129-137.	1.8	42